Company: ACHV
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059297
Chunk: 39

Company: ACHIEVE LIFE SCIENCES, INC.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 39
---
 our Executive Vice President, Commercial, since September 2017. She previously served as the Vice President, Marketing and Corporate Communications of OncoGenex Pharmaceuticals, Inc and as OncoGenex’s Senior Director, Global Oncology Commercial Development. Prior to OncoGenex, Ms. Xinos held various commercial roles in marketing, commercial development, and sales at Pfizer, Novartis, and Abbott Laboratories. She holds an undergraduate degree in Communications and a Master of Business Administration (MBA) both from the University of Illinois.

29

EXEC UTIVE COMPENSATION During fiscal year 2024, our NEOs and their respective positions were as follows: Richard Stewart, Chief Executive Officer; John Bencich, former Chief Executive Officer; Cindy Jacobs, Ph.D., M.D., President and Chief Medical Officer; and Mark Oki, Chief Financial Officer (collectively referred to in this proxy statement s NEOs, or individually an NEO). SEC rules require a discussion regarding 2024 executive compensation of our NEOs. Mr. Bencich resigned from his position as Chief Executive Officer on August 21, 2024 and Mr. Stewart was appointed to his position on August 21, 2024. Mr. Oki was appointed as Chief Financial Officer on December 5, 2024. Summary Compensation Table The following table sets forth information regarding the compensation of our NEOs for each of the fiscal years ended December 31, 2024 and 2023. The components of the compensation reported in the Summary Compensation Table are described below.

| Name and                            
 Principal Position                  |     | Year |      |     | Salary 
 ($)    |         |     |    | Stock Awards 
 ($)(1)       |         |     | Option Awards 
 ($)(2)        |         |     | Non-Equity   
 Incentive    
 Plan         
 Compensation 
 ($)(3)       |         |     | All Other Compensation ($) |         |     | Total 
 ($)   |           |
| Richard Stewart,                    |     |      | 2024 |     |        | 509,879 |     | -4 |              | 637,000 |     |               | 206,420 |     |              | 382,253 |     |                            |       — |     |       | 1,735,552 |
| Chief Executive Officer             |     | 2023 |      |     |        | 450,000 |     | -5 |              | 367,500